BYETTA PACKAGE INSERT PDF

BYETTA PACKAGE INSERT PDF

Patient Information Leaflet. Package leaflet: Information for the patient. Byetta 5 micrograms solution for injection in pre-filled pen. Byetta 10 micrograms solution . Learn about BYETTA, the BYETTA Pen. in patients with prior severe hypersensitivity reactions to exenatide or to any of the product components. PRODUCT MONOGRAPH. BYETTA® exenatide injection. µg/mL. mL prefilled pen (60 doses of 5 µg/dose) and. mL prefilled pen.

Author: Grorg Zulkigore
Country: Serbia
Language: English (Spanish)
Genre: Video
Published (Last): 16 October 2011
Pages: 96
PDF File Size: 14.64 Mb
ePub File Size: 14.87 Mb
ISBN: 241-3-93911-825-7
Downloads: 22473
Price: Free* [*Free Regsitration Required]
Uploader: Vikus

The mean apparent clearance of exenatide in humans is 9. Exenatide AUC increased proportionally over the therapeutic dose range of 5 to 10 mcg. Thin or smaller individuals can use a 45 degree angle to avoid intramuscular injection. Patients who develop severe abdominal pain while on exenatide should be evaluated as this could be a warning sign for a serious condition.

For treatment of cold symptoms, nasal decongestants may be preferable for short term, limited use 1 to 3 days as an alternative to systemic decongestants in patients taking medications for diabetes.

Moniitor blood glucose and HbA1C when these drugs are used together. Alternatively, administer before the 2 main meals of the day, approximately 6 hours or more apart. BYETTA has been pacmage with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, based on postmarketing data. Let the autoinjector come to room temperature for approximately 15 minutes before administration.

Patients treated with pasireotide may experience either hypoglycemia or hyperglycemia. Monitor for loss of glycemic control when pseudoephedrine, phenylephrine, and other sympathomimetics are administered to patients taking antidiabetic agents. This site is intended for US Consumers. Burns, diarrhea, fever, infection, ineert, thyroid disease, trauma, vomiting. Replace the blue cap after injection. Other symptoms, like headache, dizziness, nervousness, mood changes, or hunger are not blunted.

Based on glucose monitoring and clinical response, may increase after 1 month to exenatide 10 mcg subcutaneously twice daily.

  EINARBEITUNGSPLAN MUSTER PDF

Aggravation of diabetes mellitus has been reported. Exenatide is a amino acid GLP-1 agonist isolated from the salivary gland venom of the lizard Heloderma suspectum Gila monster.

Moderate Salicylates, by inhibiting prostaglandin E2 synthesis, can indirectly increase insulin secretion. A reduction in dose of oral hypoglycemic medications may be required in some patients taking orlistat.

Overall steady state AUC of digoxin was not altered. Ethanol inhibits gluconeogenesis, which can contribute to or increase the risk for hypoglycemia. The hypoglycemia or hyperglycemia which occurs during octreotide acetate therapy is usually mild, but may result in overt diabetes mellitus or necessitate dose changes in insulin or other hypoglycemic agents.

Some beta-blockers, particularly non-selective beta-blockers such as propranolol, have been noted to potentiate insulin-induced hypoglycemia and a delay in recovery of blood glucose to normal levels. Postmarketing reports of serious hypersensitivity reactions eg anaphylaxis and angioedema. Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

Call your healthcare provider right away if you have nausea, vomiting, or diarrhea that will not go away, or if you cannot take liquids by mouth. Because of the potential for clinically significant adverse reactions from exenatide in breast-fed infants, caution should be exercised, and a decision should be made whether to discontinue nursing or discontinue the drug, taking into account these potential risks against the glycemic benefits to the lactating woman.

Additionally, progestins can impair glucose tolerance. Because exenatide innsert commonly associated with gastrointestinal adverse reactions, BYETTA is not recommended in patients with severe gastrointestinal disease eg gastroparesis.

Type 2 Diabetes Medication | BYETTA® (exenatide) injection

Blood glucose should be closely monitored. Go to Patient Site. Your Name Your name is required.

If a patient with diabetes ingests alcohol, they should be counselled to to avoid ingestion of byeta on an empty stomach, which increases risk for low blood sugar. Patients receiving reserpine concomitantly with antidiabetic agents, such as incretin mimetics, should be monitored for changes in glycemic control. Limited data with exenatide in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage.

  JURNAL SENAM KEGEL PDF

Official BYETTA® (exenatide) injection Healthcare Professional Website

Go to Healthcare Professional Site. A Byetta Pen can be used for up inzert 30 days after first use. Extended-release exenatide is not a first-line therapy for patients inadequately controlled on diet and exercise.

Both first- and second-phase insulin secretion improved significantly over placebo in patients with type 2 diabetes. After first use, the Byetta Pen injector can be kept at a temperature not to exceed 77 degrees F 25 degrees C. Exenatide is approved for use with basal insulin. Diuretic-induced hypokalemia may also lead to hyperglycemia. Oral medications dependent on threshold concentrations for efficacy, such as contraceptives or antibiotics, should be taken at least 1 hour before BYETTA.

In addition, angiotensin II receptor antagonists have been associated with a reduced incidence in the development of new-onset diabetes in patients with hypertension or other cardiac disease. Changes in glycemic control isnert usually be corrected through modification of hypoglycemic therapy.

PDR Search

Extended-release injection suspension Betta single-dose Pen: Dosage adjustments of anti-diabetic medications should be considered. The clinical effects of these competing mechanisms are not known. Exenatide leads to a release of insulin only in the presence of elevated glucose concentrations. In mice, exenatide administered during gestation and lactation caused increased neonatal deaths at doses that approximate clinical exposures at the MRHD.

Cessation of nicotine therapy or tobacco smoking may result in a decrease in blood glucose. Also, while inserrt manufacturers of metformin recommend against breast-feeding while taking the drug, metformin may be a possible alternative for some patients. All other trademarks are property of their respective owners.

Previous post: